The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. The AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company sells its products through a network of direct and independent sales representatives.
Cyborg Score Rationale
As of June 2026, Encision's market cap is approximately $5M with trailing 12-month revenue of $6.3M as of September 2025. The company operates in a niche surgical device market with extremely limited scale and financial resources. High dependence on hospital adoption and reimbursement creates material execution risks.
Top Insights
Encision owns patented Active Electrode Monitoring (AEM) technology, a differentiated safety feature that prevents electrosurgical burns during laparoscopic procedures—a core clinical need that competitors address through less effective methods.
Company trades on OTC PINK exchange with market cap near $5M (June 2026) and trailing revenue of only $6.3M, indicating severe capital constraints that limit R&D, manufacturing scale, and commercial expansion capabilities.
Operates through two segments: Product (surgical instruments) and Service (electrical engineering for external parties); Product drives maximum revenue, suggesting the Service segment offers minimal financial contribution or strategic focus.
Named Competitors
Ethicon EndoSurgery Instruments — Leading surgical instruments and electrosurgical devices for minimally invasive procedures